Evaluating the Heterogeneity of Advanced Prostate Cancer by 18 F‐DCFPyL and 18 F‐FDG PET/CT in a Prospective Cohort
The Prostate · 2025
DOI: 10.1002/pros.24881 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von GuangHao Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Qilu Hospital of Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Urea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: This work was supported by the National Natural Science Foundation of China (Grant Nos. 82170790 and 81970661) to BenKang Shi, the National Natural Science Fou….
Abstract (Originalsprache)
Purpose
18 F‐DCFPyL (targeted PSMA) and 18 F‐FDG dual‐tracer PET/CT combination with next‐generation sequencing was applied in a prospective cohort of men with prostate cancer to identify the clinical and genetic characteristics with heterogeneous PET/CT imaging features.
Methods
104 men with documented prostate cancer underwent 18 F‐DCFPyL and 18 F‐FDG PET/CT, of which 83 underwent next‐generation sequencing for detecting variation of AR , TP53, RB1, PTEN , etc. Lesions were classified into DCFPyL+FDG± lesions and DCFPyL‐FDG+ lesions and analyzed for heterogeneous distribution. We divided the patients with positive lesions into DCFPyL+FDG± group and DCFPyL‐FDG+ group, then compared the differences in clinical features and genetic mutations between the two groups with CRPC.
Results
Overall, 92 men had positive lesions detected. By comparing lesion distribution with the DCFPyL+FDG ± , DCFPyL‐FDG+ disease had higher proportions of visceral metastases (4.1% vs. 1.0%, p = 0.002). DCFPyL‐FDG+ was more frequently found in CRPC cohorts, and in the CRPC cohort, patients with DCFPyL‐FDG+ lesions often had worse PSA response. Exploratory analysis showed that TP53 and/or RB1 mutations might be a risk factor for DCFPyL‐FDG+ disease (OR = 10.625, 95% CI 3.492–32.332, p < 0.001).
Conclusion
Patients with DCFPyL‐FDG+ lesions were more likely to have visceral metastases detected, be found in castration‐resistant cohorts, have TP53 and/or RB1 mutations detected, and have poor therapeutic response compared to patients with DCFPyL+FDG± lesions. Therefore, dual‐tracer ( 18 F‐DCFPyL and 18 F‐FDG) PET/CT is recommended for patients with low PSMA expression incompatible with the true burden of the disease and those with TP53 and/or RB1 mutations to better evaluate the disease burden, tumor heterogeneity, and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China.
- Department of Nuclear Medicine, Qilu Hospital of Shandong University, Jinan, China.
ORCID-Profile: GuangHao Chen, YueKai Li, ShangZhen Geng, LinChen Lv, Yong Wang, Xin Li, ShouZhen Chen, BenKang Shi
Förderung
- This work was supported by the National Natural Science Foundation of China (Grant Nos. 82170790 and 81970661) to BenKang Shi, the National Natural Science Fou…
Zitieren
APA
Chen, G., Li, Y., Geng, S., Lv, L., Wang, Y., Li, X., Chen, S., & Shi, B. (2025). Evaluating the Heterogeneity of Advanced Prostate Cancer by 18 F‐DCFPyL and 18 F‐FDG PET/CT in a Prospective Cohort. The Prostate. https://doi.org/10.1002/pros.24881
Vancouver
Chen G, Li Y, Geng S, Lv L, Wang Y, Li X, et al. Evaluating the Heterogeneity of Advanced Prostate Cancer by 18 F‐DCFPyL and 18 F‐FDG PET/CT in a Prospective Cohort. The Prostate. 2025. doi:10.1002/pros.24881
BibTeX
@article{Chen2025,
author = {Chen, GuangHao and Li, YueKai and Geng, ShangZhen and Lv, LinChen and Wang, Yong and Li, Xin and Chen, ShouZhen and Shi, BenKang},
title = {Evaluating the Heterogeneity of Advanced Prostate Cancer by 18 F‐DCFPyL and 18 F‐FDG PET/CT in a Prospective Cohort},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24881}
}
EUVIMED